802 related articles for article (PubMed ID: 31146747)
1. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
2. Novel RNA-Affinity Proteogenomics Dissects Tumor Heterogeneity for Revealing Personalized Markers in Precision Prognosis of Cancer.
Wang L; Wrobel JA; Xie L; Li D; Zurlo G; Shen H; Yang P; Wang Z; Peng Y; Gunawardena HP; Zhang Q; Chen X
Cell Chem Biol; 2018 May; 25(5):619-633.e5. PubMed ID: 29503206
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.
Arora A; Abdel-Fatah TM; Agarwal D; Doherty R; Moseley PM; Aleskandarany MA; Green AR; Ball G; Alshareeda AT; Rakha EA; Chan SY; Ellis IO; Madhusudan S
Mol Cancer Ther; 2015 Apr; 14(4):1057-65. PubMed ID: 25673821
[TBL] [Abstract][Full Text] [Related]
4. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
[TBL] [Abstract][Full Text] [Related]
5. Research-based PAM50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide screen identifies a novel prognostic signature for breast cancer survival.
Mao XY; Lee MJ; Zhu J; Zhu C; Law SM; Snijders AM
Oncotarget; 2017 Feb; 8(8):14003-14016. PubMed ID: 28122328
[TBL] [Abstract][Full Text] [Related]
7. A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
Robles J; Pintado-Berninches L; Boukich I; Escudero B; de Los Rios V; Bartolomé RA; Jaén M; Martín-Regalado Á; Fernandez-Aceñero MJ; Imbaud JI; Casal JI
J Pathol Clin Res; 2022 Nov; 8(6):495-508. PubMed ID: 36134447
[TBL] [Abstract][Full Text] [Related]
8. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
9. Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach.
Mercatelli D; Formaggio F; Caprini M; Holding A; Giorgi FM
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34750607
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of breast cancer pathological phenotypes.
Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
[TBL] [Abstract][Full Text] [Related]
12. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
13. Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.
Zhang Y; Zhang D; Meng Q; Liu Z; Xie H; Liu L; Xu F; Chen X
BMC Cancer; 2021 Aug; 21(1):918. PubMed ID: 34388989
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
[TBL] [Abstract][Full Text] [Related]
15. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
[TBL] [Abstract][Full Text] [Related]
16. Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes.
Shin J; Kim G; Lee JW; Lee JE; Kim YS; Yu JH; Lee ST; Ahn SH; Kim H; Lee C
Cancer Sci; 2016 Jun; 107(6):828-35. PubMed ID: 27002480
[TBL] [Abstract][Full Text] [Related]
17. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
19. Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
Camp NJ; Madsen MJ; Herranz J; Rodríguez-Lescure Á; Ruiz A; Martín M; Bernard PS
Breast Cancer Res Treat; 2019 May; 175(1):129-139. PubMed ID: 30673970
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.
Liu L; Chi Y; Chen J; Xue J; Deng L; Huang N; Shao J; Wu J
Sci Rep; 2017 Sep; 7(1):12382. PubMed ID: 28959047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]